Compositions and methods for treating or preventing diseases associated with oxidative stress
First Claim
1. A stable pharmaceutical composition for use in corneal collagen cross-linking, comprising (a) between about 0.015% to about 5% sodium iodide by weight, (b) riboflavin, and (c) a pharmaceutically-acceptable excipient appropriate for ocular administration, wherein the pharmaceutical composition maintains a basic pH that permits iodide ion to catalytically break hydrogen peroxide into water and oxygen.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
-
Citations
10 Claims
- 1. A stable pharmaceutical composition for use in corneal collagen cross-linking, comprising (a) between about 0.015% to about 5% sodium iodide by weight, (b) riboflavin, and (c) a pharmaceutically-acceptable excipient appropriate for ocular administration, wherein the pharmaceutical composition maintains a basic pH that permits iodide ion to catalytically break hydrogen peroxide into water and oxygen.
-
8. A stable pharmaceutical composition, comprising 0.015% sodium iodide by weight and 0.5% riboflavin by weight, and wherein the pharmaceutical composition maintains a basic pH that permits iodide ions to catalytically break hydrogen peroxide into water and oxygen.
Specification